AU2021279412A1 - Compositions and methods for treating noninflammatory pain in subjects with rheumatoid arthritis - Google Patents

Compositions and methods for treating noninflammatory pain in subjects with rheumatoid arthritis Download PDF

Info

Publication number
AU2021279412A1
AU2021279412A1 AU2021279412A AU2021279412A AU2021279412A1 AU 2021279412 A1 AU2021279412 A1 AU 2021279412A1 AU 2021279412 A AU2021279412 A AU 2021279412A AU 2021279412 A AU2021279412 A AU 2021279412A AU 2021279412 A1 AU2021279412 A1 AU 2021279412A1
Authority
AU
Australia
Prior art keywords
antibody
subject
seq
amino acid
dmard
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021279412A
Other languages
English (en)
Inventor
Kerri FORD
Hubert VAN HOOGSTRATEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Biotechnology SAS
Original Assignee
Sanofi Biotechnology SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Biotechnology SAS filed Critical Sanofi Biotechnology SAS
Publication of AU2021279412A1 publication Critical patent/AU2021279412A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2021279412A 2020-05-29 2021-05-27 Compositions and methods for treating noninflammatory pain in subjects with rheumatoid arthritis Pending AU2021279412A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063032035P 2020-05-29 2020-05-29
US63/032,035 2020-05-29
US202063077378P 2020-09-11 2020-09-11
US63/077,378 2020-09-11
EP21315081.6 2021-05-11
EP21315081 2021-05-11
PCT/IB2021/054652 WO2021240436A1 (en) 2020-05-29 2021-05-27 Compositions and methods for treating noninflammatory pain in subjects with rheumatoid arthritis

Publications (1)

Publication Number Publication Date
AU2021279412A1 true AU2021279412A1 (en) 2023-02-02

Family

ID=76269781

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021279412A Pending AU2021279412A1 (en) 2020-05-29 2021-05-27 Compositions and methods for treating noninflammatory pain in subjects with rheumatoid arthritis

Country Status (12)

Country Link
US (1) US20230192871A1 (cg-RX-API-DMAC7.html)
EP (1) EP4157450A1 (cg-RX-API-DMAC7.html)
JP (1) JP7841752B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230018443A (cg-RX-API-DMAC7.html)
CN (1) CN115697486A (cg-RX-API-DMAC7.html)
AU (1) AU2021279412A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022023949A2 (cg-RX-API-DMAC7.html)
CA (1) CA3180041A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022017828A2 (cg-RX-API-DMAC7.html)
IL (1) IL298087A (cg-RX-API-DMAC7.html)
MX (1) MX2022015030A (cg-RX-API-DMAC7.html)
WO (1) WO2021240436A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022545312A (ja) 2019-04-24 2022-10-27 サノフィ・バイオテクノロジー 関節リウマチの診断及び処置の方法
CA3142710A1 (en) 2019-06-04 2020-12-10 Sanofi Biotechnology Compositions and methods for treating pain in subjects with rheumatoid arthritis

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5215534A (en) 1991-12-02 1993-06-01 Lawrence De Harde Safety syringe system
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
US9427531B2 (en) 2010-06-28 2016-08-30 Sanofi-Aventis Deutschland Gmbh Auto-injector
US9248242B2 (en) 2012-04-20 2016-02-02 Safety Syringes, Inc. Anti-needle stick safety device for injection device
US20140155827A1 (en) 2012-12-03 2014-06-05 Mylan, Inc. Medicament information system and method
JP7101479B2 (ja) * 2014-09-16 2022-07-15 サノフィ・バイオテクノロジー 関節リウマチ患者の健康に関連した生活の質を改善するための組成物

Also Published As

Publication number Publication date
MX2022015030A (es) 2023-01-04
IL298087A (en) 2023-01-01
EP4157450A1 (en) 2023-04-05
CO2022017828A2 (es) 2022-12-20
CN115697486A (zh) 2023-02-03
JP2023527200A (ja) 2023-06-27
CA3180041A1 (en) 2021-12-02
KR20230018443A (ko) 2023-02-07
WO2021240436A1 (en) 2021-12-02
BR112022023949A2 (pt) 2022-12-27
JP7841752B2 (ja) 2026-04-07
US20230192871A1 (en) 2023-06-22

Similar Documents

Publication Publication Date Title
US20260027202A1 (en) Treatment of rheumatoid arthritis with an il-6r antibody
AU2019331024B2 (en) Dosing strategy that mitigates cytokine release syndrome for CD3/C20 bispecific antibodies
US9943594B2 (en) Methods for the treatment of rheumatoid arthritis
US20250333522A1 (en) Compositions and methods for treating pain in subjects with rheumatoid arthritis
TWI868074B (zh) 用來治療患有類風濕性關節炎之個體的方法及組成物
AU2020270966A1 (en) Human antibodies that bind ret and methods of use thereof
JP7841752B2 (ja) 関節リウマチを有する対象における非炎症性疼痛を治療するための組成物および方法
US20220242959A1 (en) Modified dosage of subcutaneous tocilizumab for rheumatoid arthritis
US20230174657A1 (en) Compositions comprising an antibody against interleukin-6 receptor for the treatment of rheumatoid arthritis and methods of using same
RU2853717C9 (ru) Композиции и способы лечения невоспалительной боли у субъектов с ревматоидным артритом
RU2853717C1 (ru) Композиции и способы лечения невоспалительной боли у субъектов с ревматоидным артритом
WO2025149845A1 (en) Treatment of subjects with polymyalgia rheumatica who have been receiving a steroid
EP4157872A1 (en) Compositions comprising an antibody against interleukin-6 receptor for the treatment of rheumatoid arthritis and methods of using same
IL265949A (en) Preparations for the treatment of rheumatoid arthritis and methods of using them
HK1195495A (en) Compositions for the treatment of rheumatoid arthritis and methods of using the same
HK1195495B (en) Compositions for the treatment of rheumatoid arthritis and methods of using the same